Tirzepatide and PCOS weight loss: what 65 lbs actually means

What did @loseitwithannie actually say?

At week 54 on tirzepatide (she spells it out as "M" paired with "J," a common TikTok workaround for platform filters), Annie says she's lost 65 pounds and is now in a maintenance phase. She also says she took tirzepatide for PCOS, obesity, and to "kick my binge eating disorder in the butt." She doses every 14 days and this week was three days late, which she blames for intense hunger. She's currently sitting at 114 pounds and notes her weight climbs during her cycle.

She does her injection on camera (audio only), mentions she "felt that one," and wraps up by asking about the "quiding" effect, which appears to be community slang for the quieted-food-noise experience common on GLP-1 medications. No dosing numbers, no brand name, no specific medical claims about curing anything. That's worth noting.

Does the science back this up?

Mostly, yes. The hunger-on-delay experience she describes is pharmacologically real, and the PCOS angle is more supported than most social media users realize.

Tirzepatide is a dual GIP/GLP-1 receptor agonist with a half-life of approximately five days (Frias et al., 2021, NEJM). A standard weekly dosing schedule means levels drop meaningfully by day 10-11. At 14-day dosing, being three additional days late puts her in a window where plasma levels are genuinely low, which would explain increased appetite. She's not imagining it.

On PCOS: tirzepatide isn't FDA-approved for PCOS, but the biology is sound. PCOS is deeply tied to insulin resistance, and both GLP-1 and GIP receptor activation improve insulin sensitivity. A 2023 review by Cena et al. in Nutrients found GLP-1 receptor agonists reduced androgen levels and improved menstrual regularity in women with PCOS. Tirzepatide's dual action likely amplifies this. "Off-label" doesn't mean unsupported.

Binge eating disorder is more complicated. There's emerging evidence that GLP-1 agonists reduce compulsive eating behaviors, possibly through dopaminergic pathways (Giel et al., 2023, Psychoneuroendocrinology), but this is not yet a clinical indication and should be managed alongside behavioral therapy, not instead of it.

What did they get wrong (or right)?

She got more right than wrong, but there are two things worth flagging.

First, dosing every 14 days for tirzepatide is non-standard. The approved interval is weekly (Zepbound, Mounjaro). Extended intervals aren't necessarily dangerous, but the hunger rebound she experienced is a predictable consequence of that schedule, not a mystery. She shouldn't normalize it as just "being human." If a patient is consistently forgetting injections on a biweekly schedule, that's a conversation to have with a prescriber about weekly dosing or a different administration strategy.

Second, she handles the PCOS framing reasonably well. She doesn't say tirzepatide "cures" PCOS. She says she took it "for" PCOS alongside other goals. That's a meaningful distinction and she deserves credit for not overclaiming. The weight at 114 pounds is mentioned without height context, so we can't assess whether she's at a healthy weight, but that's a framing gap, not a false claim.

• Correct: hunger rebounds are real at extended dosing intervals
• Correct: PCOS and obesity are clinically linked to insulin resistance, making GLP-1 class drugs relevant
• Needs nuance: BED management on tirzepatide alone is not an established protocol
• Needs nuance: 14-day dosing is off-label and the consequences she experienced are predictable

What should you actually know?

A few things that the video gestures at but doesn't fully land.

Tirzepatide is not approved to treat PCOS or binge eating disorder. Using it for those purposes is off-label and should be done under medical supervision with clear documentation of clinical rationale. Off-label use is legal and common in medicine, but it carries different liability and monitoring standards than approved indications.

The "quiding" or food noise reduction effect she references at the end is real and documented. Blomain et al. (2016, ISRN Obesity) described appetite suppression mechanisms, and more recent qualitative data from SURMOUNT trial participants supports the food noise framing. But it varies significantly between patients. Don't assume your experience will match hers.

Weight during the menstrual cycle fluctuates by 1-5 pounds for most women due to water retention, not fat gain (Becker et al., 2017, Physiology and Behavior). Annie's observation about cycle week weight changes is normal physiology, not a medication failure.

Finally, 54 weeks is a meaningful data point. Long-term adherence to GLP-1 therapy is one of the real-world challenges the clinical trials don't fully capture. Her candor about forgetting doses is useful for other patients to hear.